Press release
Global Clostridium Difficile Infections Clinical Trial Surges as 20+ Companies Advance 22+ Therapies, Highlights DelveInsight's Comprehensive Clinical Assessment
Clostridium Difficile Infections Clinical Trial
The report delivers an in-depth commercial and clinical assessment of investigational and marketed therapies, ranging from early-stage research to approved products. It features extensive drug profiles outlining mechanisms of action, clinical outcomes, regulatory achievements, and key development updates, including technological advancements, partnerships, mergers and acquisitions, financing activities, and other strategic developments.
According to DelveInsight's recent analysis, the global Clostridium difficile infections (CDI) pipeline comprises more than 20 active companies developing over 22 therapeutic assets. The study provides a thorough review of ongoing clinical trials, therapeutic approaches, administration routes, and the latest advancements shaping the CDI treatment environment.
Download a complimentary sample report @ https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Insights from the Clostridium Difficile Infections Pipeline Report
• A significant number of international companies are actively progressing innovative CDI therapies, reflecting notable advancements in recent years.
• Leading organizations involved in the CDI pipeline include Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Lumen Bioscience, Summit Therapeutics, Finch Therapeutics, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, and Replidyne, among others.
• Noteworthy emerging candidates such as ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER-109, VE303, MGB-BP-3, and CRS3123 are expected to play a transformative role in the future CDI therapeutic landscape.
Recent Clinical and Pipeline Advancements in Clostridium Difficile Infections
• June 2025: Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI). The Company today announced the publication of results in Lancet Microbe of its Phase 2b clinical study entitled: Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomized, double-blind, active-controlled, multicenter study. The senior author is Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, and Principal Investigator for microbiology and microbiome aspects of the IBZ clinical trial program, and a co-author of the IDSA (Infectious Diseases Society of America) C. difficile Treatment Guidelines.
• April 2025: Lumen Bioscience announced encouraging top-line results from the sentinel cohort of its RePreve study assessing LMN-201, an orally administered biologic combination therapy intended for use alongside standard antibiotics to improve clinical outcomes.
• February 2025: Microbiotica shared updated findings on MB097's mechanism of action during the AACR Immuno-Oncology Conference.
• January 2025: Vedanta Biosciences reported new data from its Phase II CONSORTIUM study of VE303 in Nature Medicine, strengthening evidence for its potential in preventing recurrent CDI.
• January 2025: MaaT Pharma disclosed top-line findings from its Phase III ARES trial evaluating MaaT013 in patients with GI-aGvHD.
• January 2025: PureTech Health released updated results from Vedanta's Phase II clinical study of VE303.
• January 2025: Seres Therapeutics presented new exploratory biomarker insights from its Phase Ib SER-155 clinical trial.
Clostridium Difficile Infections Overview
Clostridium difficile infection (CDI) is a toxin-producing bacterial condition affecting the colon, frequently associated with antibiotic-driven disruption of normal gut microbiota. Clinical manifestations vary from mild diarrhea to severe and potentially fatal colitis. Although CDI is most prevalent among elderly and hospitalized individuals, recurrence remains a persistent clinical concern. Standard management typically involves stopping the inciting antibiotic and initiating targeted therapies such as vancomycin or fidaxomicin.
Request a complimentary sample PDF for in-depth therapeutic analysis: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Clostridium Difficile Infections Therapies Under Clinical Evaluation
• ADS024 - Adiso Therapeutics
• DNV3837 - Deinove
• Ibezapolstat - Acurx Pharmaceuticals
• LMN-201 - Lumen Bioscience
• Ridinilazole - Summit Therapeutics
• CP101 - Finch Therapeutics
• SER-109 - Seres Therapeutics
• VE303 - Vedanta Biosciences
• MGB-BP-3 - MGB Biopharma
• CRS3123 - Replidyne
Routes of Administration Covered in the CDI Pipeline
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Categories Represented in the CDI Pipeline
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Clostridium Difficile Infections Therapeutic Evaluation Encompasses:
• Classification by product type, development stage, administration route, and molecular class
• Review of both active and discontinued development programs
• Mechanistic insights and evaluation of monotherapy versus combination strategies
• Analysis of licensing agreements, collaborations, funding activities, and R&D advancements
DelveInsight's CDI pipeline assessment covers more than 22 assets across multiple development phases, including:
• Phase III
• Phase II
• Phase I
• Preclinical and discovery stages
• Inactive or terminated programs
Additional product-specific insights are available in the full report. Download the Clostridium Difficile Infections pipeline study to explore detailed information on emerging therapies: https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Companies in the Clostridium Difficile Infections Therapeutics Market
Prominent players operating in the CDI therapeutics space include Novartis, Astellas, Eli Lilly, AstraZeneca, Actelion Pharmaceuticals, Merck & Co., Baxter, Sanofi, Pfizer, and Mylan, among others.
Clostridium Difficile Infections Market Growth Drivers
• Increasing global incidence of CDI
• Rising antibiotic consumption worldwide
Clostridium Difficile Infections Market Challenges
• Insufficient disease awareness
• Elevated diagnostic and treatment expenditures
• Complexity in treating severe and recurrent CDI cases
Scope of the Pipeline Insight Report
• Geographical Coverage: Global
• Key Companies: Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Lumen Bioscience, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others
• Key Therapies: ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER-109, VE303, MGB-BP-3, CRS3123, and others
• Therapeutic Assessment: Evaluation of currently marketed and emerging CDI treatments
• Market Dynamics: Detailed review of market drivers and barriers
Download a Sample PDF to gain deeper insights into Clostridium Difficile Infections drugs and therapeutic advancements: https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Information
Ankit Nigam
Manager - Marketing
info@delveinsight.com
+1 469 945 7679
About DelveInsight
DelveInsight is a specialized business consulting and market research firm dedicated exclusively to the life sciences sector. The company supports pharmaceutical organizations with comprehensive, end-to-end strategic solutions designed to enhance operational performance. Through its healthcare consulting services, DelveInsight assists clients with market analysis, strategic planning, and practical approaches to accelerate growth and effectively address industry challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Clostridium Difficile Infections Clinical Trial Surges as 20+ Companies Advance 22+ Therapies, Highlights DelveInsight's Comprehensive Clinical Assessment here
News-ID: 4402162 • Views: …
More Releases from DelveInsight Business Research
Surgical Site Infections Clinical Trial Insight 2026: More Than 5 Companies Adva …
(Albany, United States) As per DelveInsight's recent evaluation, the global Surgical Site Infections (SSI) pipeline features over five prominent companies actively progressing more than five potential therapeutic candidates. The report presents a thorough examination of ongoing clinical trials, therapeutic strategies, mechanisms of action, administration routes, and recent advancements within the development landscape.
DelveInsight's "Surgical Site Infections Pipeline Insight, 2026" publication provides a comprehensive assessment of the present clinical development scenario and…
Global Interstitial Lung Disease Pipeline Surpasses 120+ Therapies: Major FDA Mi …
Global Interstitial Lung Disease Pipeline Surpasses 120+ Therapies: Major FDA Milestones and Clinical Progress Highlighted by DelveInsight
DelveInsight, a prominent life sciences market intelligence and consulting organization, has unveiled its newest report, "Interstitial Lung Disease Pipeline Insight, 2026" delivering a comprehensive analysis of the fast-evolving therapeutic environment for Interstitial Lung Disease (ILD). With over 120 companies advancing more than 120 therapeutic assets, the ILD pipeline is witnessing remarkable scientific innovation, clinical…
Spasticity Clinical Trial Analysis 2026: In-Depth Evaluation of 12+ Emerging The …
According to the most recent insights from DelveInsight, the global Spasticity pipeline encompasses more than 10 active pharmaceutical companies progressing over 12 investigational drug candidates. The report provides a comprehensive assessment of ongoing clinical trials, mechanisms of action, treatment strategies, routes of administration, and key developmental milestones that are reshaping the Spasticity therapeutic landscape.
DelveInsight's publication, "Spasticity Pipeline Insight, 2026" presents a detailed analysis of the present clinical development scenario along…
Advanced Melanoma Pipeline Strengthens With 60+ Investigational Assets and 55+ A …
Advanced melanoma developers include Replimune, IO Biotech, BioNTech SE, Perspective Therapeutics, Agenus Inc., Dragonfly Therapeutics, Iovance Biotherapeutics, Novartis, AstraZeneca, Exelixis, Immunocore, BeiGene, Biocad, Merck Sharp & Dohme, Genentech, Amgen, and others.
DelveInsight's Advanced Melanoma Pipeline Insight 2026 delivers a detailed assessment of the dynamic research environment, profiling more than 55 biopharma companies and over 60 therapeutic candidates currently progressing in advanced melanoma. The study offers comprehensive therapy profiles spanning clinical and…
More Releases for Clostridium
Veterinary Clostridium Vaccine Market
The veterinary clostridium vaccine market plays a crucial role in the prevention of clostridial diseases in livestock and companion animals. Clostridial infections, caused by bacteria from the Clostridium genus, can lead to severe health issues and significant economic losses in the agriculture sector. Vaccination is one of the most effective methods to control these infections, which include conditions like enterotoxemia, tetanus, and gas gangrene. The growing awareness of animal health,…
Clostridium Diagnostics Market Analysis, Size, Share & Trends | 2031
In recent years, the global Clostridium Diagnostics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Clostridium Diagnostics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Clostridium Diagnostics Market to Witness Astonishing Growth by 2030
Clostridium Diagnostics market is projected to grow at a CAGR of 7.5% from 2024 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium-related diseases, rising demand for accurate and rapid diagnosis, and growing awareness about Clostridial infections. Important changes in the business allow key players to attain larger profits. This Clostridium Diagnostics Market study report is the best way to make changes with…
Clostridium Diagnostics Market - Empowering Precision, Defeating Infection: Adva …
Newark, New Castle, USA - new report, titled Clostridium Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Clostridium Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Clostridium Diagnostics market. The report offers an overview of the market, which…
Clostridium Vaccine Market Size, Price, Share | Forecast to 2027
Latest Updated Report 2023, The Global Clostridium Vaccine Market to Growing A CAGR of % during forecast period of 2023-2027. The Market is segmented by Global Clostridium Vaccine Market Breakdown by Application (Veterinary Clinic, Veterinary Hospital) by Type (General Type) and by Geography (North America, South America, Europe, Asia Pacific, MEA).
The Clostridium Vaccine Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It…
Global Clostridium Difficile Immunoassays Market - Opportunities & Forecasts, 20 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global clostridium difficile immunoassays market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
